Global Blood Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GBT research report →
Range $36 – $110
Price Chart
About the company
Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical firm dedicated to discovering, developing, and providing therapies for patients suffering from sickle cell disease (SCD) who currently lack adequate treatment options. Its marketed product, Oxbryta tablets, offers a once-daily, oral treatment for SCD.
- CEO
- Ted Love
- IPO
- 2015
- Employees
- 457
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on GBT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $0
- P/E
- -14.21
- PEG
- 0.88
- P/S
- 0.00
- P/B
- 21.94
- EV/EBITDA
- 0.09
- Div Yield
- 0.00%
- Gross Margin
- 98.30%
- Op Margin
- -147.44%
- Net Margin
- -155.63%
- ROE
- -98.96%
- ROIC
- -33.51%
Latest fiscal year · YoY change
- Revenue
- $194.75M+57.3%
- Gross Profit
- $191.43M+57.1%
- Op Income
- $-287,147,000
- Net Income
- $-303,091,000-22.4%
- EPS
- $-4.82-19.3%
- OCF Growth
- -21.2%
- FCF Growth
- -17.9%
- 52W High
- $73.02
- 52W Low
- $21.65
- Beta
- 0.46
- RSI (14)
- 77
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Global Blood Therapeutics reported strong Q1 Oxbryta momentum, driven by the pediatric launch and improving adult demand, and said revenue should step up again in Q2 despite payer and COVID headwinds.· May 4, 2022
- Q1 Oxbryta net revenue was $55.2 million, up about 41% year over year and in line with guidance.
- The company said it delivered more than 1,200 new prescriptions in Q1, its strongest demand quarter since Q1 2020, with early pediatric uptake leading the way.
- Gross-to-net was 16.3% in Q1, and management expects it to rise toward about 25% by midyear.
- Q2 revenue guidance was $63 million to $65 million, with management pointing to continued NRx growth partly offset by pediatric payer timing and higher gross-to-net.
- Pipeline updates included a planned mid-2022 start for GBT601 Phase 2/3 and ongoing enrollment in inclacumab THRIVE studies.
Total net revenue from Oxbryta sales was $55.2 million in Q1 2022, up approximately $16 million or 41% year over year, and in line with guidance of $54 million to $56 million. Gross-to-net was 16.3% in the quarter, about 0.5 percentage points higher than Q4, and basic/diluted loss per share was $1.26 versus $1.21 a year ago; net loss was $81 million versus $75 million in Q1 2021. R&D expense was $53 million versus $51 million last year, SG&A was $75 million versus $59 million, and cash, cash equivalents and marketable securities were $662 million at quarter-end versus $735 million at year-end 2021. For Q2 2022, management guided to revenue of $63 million to $65 million, implying sequential growth of 14% to 18%; it said full-year revenue should grow over the remainder of 2022, but did not give annual revenue guidance.
Ted Love framed the quarter as a strong start to the year, highlighting the pediatric Oxbryta launch, better new-prescription trends in patients 12 and older, and broader momentum from awareness-building and real-world evidence. He said the company is increasingly confident in Oxbryta and the pipeline, and expects multiple growth opportunities in the coming quarters and years, including Europe and new SCD programs. His tone was optimistic but measured, with repeated references to improving COVID conditions and the need to see more normal in-person care before giving longer-term guidance.
Jeff Farrow emphasized that Q1 results were in line with expectations and that the company remains well funded, ending the quarter with $662 million in cash, cash equivalents and marketable securities. He said Q1 gross-to-net was 16.3% and expects it to rise incrementally toward about 25% by midyear, driven by payer mix and co-pay support dynamics. He also noted that cost of sales should increase in 2022 as fully expensed inventory is sold through, while both R&D and SG&A were slightly below expectations in Q1 due to timing of expenses that should hit later in the year. For Q2, he pointed to pediatric coverage timing, gross-to-net, and a distributor shipping pattern at quarter-end as the main reasons revenue guidance does not fully mirror the strong NRx trend.
Analysts focused on how much of the Q1 prescription strength came from the pediatric launch versus underlying adult demand, and management said the biggest spike was early in the quarter when many younger patients were ready to start therapy. They also pressed on why revenue guidance trails NRx momentum; management pointed to the lack of broad pediatric payer coverage, higher gross-to-net, and quarter-end shipment timing that can push revenue into the following quarter. On GBT601, management clarified that the six Phase 1 participants are restarting at 150 mg by invitation, that no new participants will be added to that restart cohort, and that the formal Phase 2/3 study is a separate dose-finding program planned for mid-2022.
The bull case from the call is that Oxbryta appears to be gaining traction across both pediatric and older patient groups, with more than 1,200 Q1 new prescriptions and growing prescriber participation. Management also described broad payer progress for ages 4 to 11, strong early feedback on the pediatric launch, and a pipeline with multiple shots on goal, including inclacumab and GBT601.
The main risks discussed were persistent COVID-related caution, especially lower in-person visits for sickle cell patients, and incomplete pediatric payer coverage that delays revenue recognition. Management also flagged rising gross-to-net and said Q2 revenue may not fully capture the NRx strength because of coverage timing and quarter-end shipment dynamics. Longer term, they said they are not ready to provide annual guidance because the pandemic and possible variants still create uncertainty around patient visits and demand.
AI summary of the company's earnings call · Paraphrased · Not investment advice
of shares held by institutions
1 13F filers
Buy/sell ratio 0.11. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for GBT, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Roosevelt Investment Group LLC | 146.84K | ▼ 655.54K |
| Grace Capital | 130.95K | ▲ 2.30K |
| Parametric Portfolio Associates LLC | 94.06K | ▼ 20.25K |
| Jefferies Group LLC | 46.34K | ▲ 30.98K |
| S. Muoio & Co. LLC | 40.71K | ▲ 40.71K |
| Taylor Wealth Management Partners | 27.92K | ▼ 1.70K |
| Sarissa Consulting LLC | 26.00K | ▲ 26.00K |
| First Midwest Bank Trust Division | 13.82K | ▼ 1.10K |
| Amalgamated Financial Corp. | 10.10K | ▲ 10.10K |
| Wipfli Financial Advisors LLC, | 145 | ▲ 145 |
| Siena Capital LLC | 4 | 0 |
Held by 1 ETFs
Biggest fund positions in GBT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 5, 22 | PERRY MARK L | sell | 5,600 |
| Oct 5, 22 | PATRICK DEVAL L | sell | 5,600 |
| Oct 5, 22 | Morrison Scott W | sell | 5,600 |
| Oct 5, 22 | Thompson Alexis A. | sell | 3,600 |
| Oct 5, 22 | YARNO WENDY L | sell | 30,000 |
| Oct 5, 22 | Pizzo Philip A. | sell | 7,500 |
| Oct 5, 22 | Svoronos Dawn | sell | 5,600 |
| Oct 5, 22 | PIERCE GLENN | sell | 5,600 |
| Oct 5, 22 | Smith-Whitley Kim | sell | 18,120 |
| Sep 28, 22 | JOHNSON DAVID LEE | other | 22,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GBT coverage
Recent articles, reports, and earnings notes.
No research on GBT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GBT report →BMTC Group (TSE:GBT) Stock Price Crosses Below 50-Day Moving Average – What’s Next?
defenseworld.net · Feb 7
Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
seekingalpha.com · Sep 16
GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT
businesswire.com · Aug 31
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates AAWW, GBT, CYBE, AVLR
prnewswire.com · Aug 22
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GBT, AVLR, CYBE, SBCF
prnewswire.com · Aug 15
Get ready for more merger mania in pharma sector the rest of the year
marketwatch.com · Aug 9
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings
zacks.com · Aug 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.